Clinical implications of the ODAC vote in favor of polatuzumab vedotin for untreated DLBCL

Following a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting, the Lymphoma Hub was pleased to speak Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, What are the clinical implications of the ODAC vote for a favorable benefit/risk profile of polatuzumab vedotin for untreated diffuse large B-cell lymphoma (DLBCL)? 

Nowakowski discusses findings from the phase III POLARIX study (GO39942; NCT03274492) comparing polatuzumab vedotin plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisolone) with the current standard of care, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), in patients with previously untreated DLBCL. Nowakowski summarizes the data on progression-free survival, overall survival, and toxicities, referring to the heterogeneity of patients in this study. Finally, Nowakowski discusses polatuzumab vedotin in the context of current standard of care treatments and the global clinical impact this may have.